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In this study we evaluated the commercially available LightMix® RT-PCR assay for Helicobacter pylori detection
and identiﬁcation of clarithromycin (CLR) resistance in culture and clinical specimens (gastric biopsies and
stool). The H. pylori LightMix® RT-PCR detects a 97 bp long fragment of the 23S rRNA gene and allows the iden-
tiﬁcation of 3 distinct point mutations conferring CLR resistance via melting curve analysis. The performance of
the H. pylori LightMix® RT-PCR was evaluated using a set of 60 H. pylori strains showing phenotypical CLR sus-
ceptibility or CLR resistance (Minimum inhibitory concentrations from 0.016 to 256 mg/L). We found high con-
cordance (95%) between phenotypical CLR resistance screening by E-Test® and the Lightmix® RT-PCR.
Discrepant results were veriﬁed by sequencing of the 23S rRNA gene that always conﬁrmed the results obtained
by Lightmix® RT-PCR. Furthermore, H. pyloriwas detected in clinical biopsy and stool specimens by Lightmix®
RT-PCR that identiﬁed the correct H. pylori genotype. The LightMix® RT-PCR is an accurate, sensitive and
easy to use test for H. pylori and CLR resistance detection and can therefore be readily implemented in any
diagnostic laboratory.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Helicobacter pylori is a Gram-negative bacterium that can cause
chronic stomach infections and is therefore known as the main cause
of gastric ulcers and subsequently for the development of gastric cancer
if untreated (Thaker et al., 2016). Therefore, eradication therapy of
H. pylori is necessary in order to prevent the development of gastric ad-
enocarcinoma (Fukase et al., 2008) as well as for the successful treat-
ment of mucosa-associated lymphoid tissue (MALT) lymphoma
(Fischbach et al., 2004). The proposed ﬁrst-line empirical treatment
for an H. pylori infection is a triple therapy including a proton pump in-
hibitor (PPI), clarithromycin (CLR) and amoxicillin or metronidazole
(Malfertheiner et al., 2017). Over the past 20 years increasing resistance
rates of H. pylori to macrolides such as CLR have been reported
(Megraud et al., 2011), with a prevalence of CLR resistance in Europe
at present around 19% (Megraud et al., 2013). The increase in CLR resis-
tance impairs the effectiveness of empiric triple regimens (Fischbach
et al., 2002). As a result a vast majority of patients show unacceptably
low treatment success for ﬁrst-line empirical treatment containing
CLR, with only 18% exceeding 85% and approximately 60% failing to
reach 80% eradication rates (Graham and Fischbach, 2010). Conse-
quently, empiric triple therapy is just recommended in regions with
CLR resistance rates lower 20% without prior susceptibility testing
(Malfertheiner et al., 2017). Molecular methods, like RT-PCR, can be
used to determine CLR resistance before the start of empiric therapy
and can achieve increased H. pylori eradication rates by individually
adapted antibiotic therapy. As second line therapy for H. pylori eradica-
tion, either a bismuth containing quadruple therapy or a levoﬂoxacin
containing triple therapy is recommended (Malfertheiner et al., 2017;
Mégraud, 2013).
In Switzerland, the current algorithm forH. pylori detection is to per-
form an endoscopy, fromwhich biopsy-based tests such as rapid urease
screening, histology and culture are done (Malfertheiner et al., 2017).
Susceptibility testing from culture is recommended to ensure the best
choice of antibiotics (Cammarota et al., 2004), especially after treatment
failure with ﬁrst-line and second-line antibiotics. In times of increasing
antibiotic resistance, the need for more rapid resistance screening
procedures that replace conventional cultural methods gain importance
as H. pylori is a fastidious and slow growing bacterium that can
make susceptibility testing from culture a time consuming and
challenging task.
Here, we introduce the commercially available Lightmix® RT-PCR
method that is based on the detection of point mutations in the gene
encoding the 23S ribosomal subunit (23S rDNA) of H. pylori. There are
three main point mutations in the 23S rDNA (A2142G, A2143G and
A2142C) that are known to induce macrolide resistance. It is possible
to distinguish 3 types of point mutations from the wild-type sequence
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in the 23S rDNA with the Lightmix® hybridization probe via melting
curve analysis. As known from previous studies, resistance levels vary
depending on the mutation in the 23S rDNA, permitting an evaluation
of treatment outcome depending on the detected point mutation.
More precisely, A2142G point mutations are related to higher (N
64 mg/L) minimum inhibitory concentrations (MICs) and lower (b
64 mg/L) MICs are often associated with A2143G mutations, whereas
A2142C point mutations are rarely found and thus no statement can
be made on the CLR resistance level they convey (van Doorn et al.,
2001; Versalovic et al., 1997).
Besides the detection of H. pylori and the identiﬁcation of CLR resis-
tance in biopsies, which can just be retrieved from patients via an inva-
sive endoscopy, H. pylori can be detected in stool specimens using RT-
PCR. Evaluation from various studies using RT-PCR in stool samples
showed exceptional speciﬁcity values, but sensitivity was rather low
ranging from 62.5% to 73.0% (Falsaﬁ et al., 2009; Lottspeich et al.,
2007; Schabereiter-Gurtner et al., 2004; Şen et al., 2005).
The aim of this study was to compare CLR susceptibility testing by
E®-Test and the Lightmix® RT-PCR using a set of 60 H. pylori strains
showing phenotypical CLR susceptibility or CLR resistance (Minimum
inhibitory concentrations from 0.016 to 256 mg/L). Furthermore, we
evaluated H. pylori and CLR resistance detection in clinical specimens
(biopsy and stool) by Lightmix® RT-PCR.
2. Materials and methods
2.1. H. pylori strains used in the study
In this study a set of H. pylori strains (N= 60) from the culture col-
lection of the Institute of Medical Microbiology, University of Zurich,
were used. These strains were isolated between 2013 and 2015 from
gastric biopsies thatwere sent to the laboratory for susceptibility testing
after CLR treatment failure. The strains were intentionally selected
based on their phenotypic resistance status to get an evenly distributed
number of CLR susceptible (MIC ≤0.25 mg/L) and CLR resistant strains
(0.5 b MIC). After thawing, the isolates were incubated on Brucella
Agar plates (Becton Dickinson, Allschwil, Switzerland) for 3 days at
37 °C in a microaerophilic atmosphere (90% N2, 5% CO2, 5% O2) using a
gas generator (CampyGen; Oxoid, Basingstoke, England). Subcultures
weremade from theH. pylori isolates after 3 days to obtain enough bio-
mass for the E-Test® (bioMérieux, Marcy l'Etoile, France) and to per-
form DNA extraction using InstaGene®. Two colonies from each
bacterial subculture were suspended in 0.85% NaCl. DNA was extracted
using InstaGene® (Bio-Rad, Hercules, CA, USA), following the
manufacturer's recommendations with the following modiﬁcations:
centrifugation for 10minutes instead of 1 minute at 10′000 g before re-
moval of the supernatant, incubation at 56 °C for two hours instead of
30 minutes, and incubation for 10 instead of 8 minutes at 96 °C instead
of 100 °C. AllH. pylori strains (N=60)were analyzed by E-Test® and by
Lightmix® RT-PCR (TIBMolbiol, Berlin, Germany).
2.2. Phenotypical CLR susceptibility testing by E-Test®
The H. pylori culture was adjusted to a McFarland Standard of 3
(McFarland, 1907). A rapid urease test (Becton Dickinson) was
performed with each H. pylori strain, following the producer's rec-
ommendations, before carrying out the E-Test® to conﬁrm a success-
ful H. pylori growth and exclude contamination. A stripe containing
CLR (bioMérieux, 0.016–256 mg/L) was put on a Mueller Hinton
agar plate with horse blood (Becton Dickinson). The plates were in-
cubated in a microaerobic atmosphere at 37 °C for 3 days. Subse-
quently, the MIC was determined using a light microscope (Leica
M80, Leica Microsystems). Susceptibility interpretation was per-
formed, according to EUCAST (EUCAST, 2016), applying a clinical
breakpoint of ≤0.25 mg/L for CLR susceptible and N0.5 mg/L for CLR
resistant strains.
2.3. Lightmix® RT-PCR assay and melting curve analysis
For the RT-PCR, the extracted DNA was added to a mixture
consisting of Roche PCR-grade water (Roche, Rotkreuz, Switzerland), a
LightCycler® DNA multiplex master mix (Roche) and the Lightmix®
primers and probes (TIBMolbiol). We followed the RT-PCR mastermix
composition guidelines and the LightCycler® (LC) ampliﬁcation proto-
col provided by TIBMolbiol. The RT-PCR was performed on a
LightCycler480-II® (Roche). The RT-PCR ampliﬁcation protocol was
followed by a melting curve analysis on the LightCycler480-II® instru-
ment, following the LC protocol from TIBMolbiol.
2.4. Performance of the Lightmix® RT-PCR assay
A dilution series (from 109 to 103 CFUs/ml) of 4 H. pylori cultures
(wild-type, A2142G, A2142C and A2143G genotype) was done in
0.85% NaCl to determine the sensitivity of H. pylori detection by
Lightmix® RT-PCR. DNA was extracted from each dilution using
InstaGene® as stated above and analyzed by Lightmix® RT-PCR and
melting curve analysis.
To determine the speciﬁcity of the Lightmix® primers and probes,
we chose a set of commensal and pathogenic bacteria that may occur
in clinical specimens (Table 1). These bacterial isolates were obtained
from the strain collection of the Institute of Medical Microbiology and
cultured on COS blood agar or McConkey agar plates (BD) at 37 °C.
Table 1
Bacterial strains isolated from clinical specimens used for determining the speciﬁcity of
the H. pylori Lightmix® RT-PCR.
Sample_ID Species Material RT-PCR
Result
Camplyobacter
spp.
2016112726 C. jejuni stool +
2016112690 C. jejuni stool +
2016112682 C. coli stool +
50205 C. fetus stool +
Corynebacterium
spp.
51573 C. amycolatum culture -
5063 C. propinquum culture -
48036 C. imitans culture -
1532 C. pseudodiphtheriticum culture -
Escherichia sp.
52289 E. coli culture -
Salmonella spp.
48504 S. enterica culture -
1657465 S. typhimurium culture -
Staphylococcus
spp.
39614 S. aureus culture -
53962 S. caprae culture -
53440 S. epidermidis culture -
54607 S. gallinarum culture -
54669 S. haemolyticus culture -
42000 S. hominis culture -
53225 S. lugdunensis culture -
53222 S. pettenkoferi culture -
52557 S. pasteuri culture -
Streptococcus
spp.
39702 S. anginosus culture -
3685 S. constellatus culture -
47158 S. bovis culture -
44666 S. gallolyticus culture -
3846 S. gordonii culture -
19733 S. intermedius culture -
24657 S. mitis culture -
30611 S. mutans culture -
48502 S. oralis culture -
3290 S. salivarius culture -
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DNA was extracted using InstaGene® as stated above and analyzed by
Lightmix® RT-PCR.
2.5. Sequencing of the 23S rDNA
To verify the detected 23 rDNA sequence, all RT-PCR products were
sequenced. After RT-PCR, the ampliﬁcation products were puriﬁed
using the QIAquick PCR Puriﬁcation Kit (QIAGEN), following the
producer's recommendations. The BigDye® sequencing kit solutions
as well as the H. pylori primers were added to our template DNA. A
Veriti™ Thermal Cycler (Applied Biosystems, Forster City, CA, USA)
was used for the cycle sequencing program. This program included an
initial denaturation of the templates at 96 °C for 1 minute, followed by
25 cycles that each consisted of a denaturation at 96 °C for 10 seconds,
and an annealing and elongation step for 1 minute at 60 °C. The cycle se-
quencing productswere then cleaned using Performa®DTRGel Filtration
Cartridges (EdgeBio, Gaithersburg, CA, USA) and centrifuged for
2 minutes at 750 rpm. The cleaned ampliﬁcation products were se-
quenced on an ABI PRISM® 3130 Genetic Analyzer (Applied Biosystems).
2.6. Clinical biopsy and stool specimens used in the study
H. pyloriwas cultivated from fresh biopsies (N=6) thatwere sent to
our institute. Subculturing was not necessary as enough biomass was
obtained to perform the E-Test®. For the Lightmix® RT-PCR, DNA was
extracted from the biopsy using the EZ1® DNA Tissue Kit (Qiagen,
Hilden, Germany), following themanufacturer's recommendations. Re-
sults from H. pylori and CLR resistance detection by E-Test® and by
Lightmix® RT-PCR were compared for the 6 gastric biopsy specimens.
To determine the sensitivity ofH. pylori detection in stool specimens,
a dilution series (from 109 to 102 CFUs/ml) was done with 3 H. pylori
cultures (wild-type, A2142G and A2143G genotype); 100 μL of each di-
lution was spiked into 900 μL of liquid stool and DNA was extracted
from the spiked stool samples with the PSP® spin stool DNA kit
(Invisorb Stratec, Berlin, Germany), following the producer's recom-
mendations. H. pylori and CLR resistance was detected by Lightmix®
RT-PCR and melting curve analysis. To determine the speciﬁcity of
H. pylori detection in stool samples, four Campylobacter sp. positive
stool samples were processed with the PSP® spin stool DNA kit
(Invisorb Stratec, Berlin, Germany), following the producer's recom-
mendations, and analyzed by Lightmix® RT-PCR.
2.7. Ethics
The research was conducted in accordance with the Declaration of
Helsinki and national and institutional standards.
3. Results
3.1. Performance of the H. pylori Lightmix® RT-PCR
The H. pylori Lightmix® RT-PCR detected 109 to 103 23S rRNA gene
copies per ml and showed a clear melting peak independent of gene
copy number (Fig. S1). Melting curve analysis showed clear melting
temperature (Tm) shifts between the wild-type strains and strains
showing nucleotide mismatches with the 23S rDNA probe. The
H. pyloriwild-type showed a distinct Tm at 63 °C, whereas themutation
variants A2142C, A2143G and A2142G showed a Tm at 54 °C, 56 °C and
59 °C, respectively (Fig. S1).
3.2. CLR resistance detection by E-Test® and Lightmix® RT-PCR using H.
pylori strains
We determined the MIC of CLR by E-Test® for 60 H. pylori strains
(Fig. 1, Table S1). Accordingly, 20/60 strains were classiﬁed as CLR sus-
ceptible (MIC ≤0.25 mg/L) and 40/60 strains were classiﬁed as CLR
resistant (0.5 b MIC). All 20 H. pylori strains that were determined as
CLR susceptible by E-Test® showed a wild-type genotype at a Tm of
63 °C in melting curve analysis (Fig. 2a). Among the 15 CLR resistant
strains with a 0.5 b MIC b256, 13/15 showed a Tm at 56 °C (A2143G)
and 2/15 a Tm at 63 °C (Fig. 2b) like the CLR susceptible wild-type
strains. The two H. pylori strains with a Tm at 63 °C had a MIC of 48
and 128mg/L. 23S rDNA sequencing conﬁrmed thewild-type genotype
for both H. pylori isolates (Fig. 1, Table S1). Among the 25 CLR resistant
H. pylori strains withMIC ≥256, 1/25 showed a Tm at 54 °C (A2142C), 9/
25 a Tm at 56 °C (A2143G) and 14/25 showed a Tm at 59 °C (A2142G)
(Fig. 2c). There was one heterozygous strain that carried two different
point mutations (A2142G and A2143G), one in each 23S rRNA gene.
One strain showed a Tm at 63 °C, which infers a wild-type genotype,
though a MIC ≥256 was detected by E-Test®.
Discrepant results between E-Test® and RT-PCRwere obtained for 3
H. pylori strains that showed a CLR resistant phenotype, whereas a Tm of
63 °C was detected in melting curve analysis, indicating a CLR suscepti-
ble H. pylori wild-type. The wild-type sequence was conﬁrmed by 23S
rDNA sequencing for all 3 H. pylori isolates (Fig. 1, Table S1). Overall, a
concordance of the two methods was found in 57 of the 60 samples
(95%) (Table 2). This coincides with previous studies that showed con-
cordance rates between E-Test® and laboratory-developed PCR assays
ranging from 71.2% to 98.4% (Chisholm and Owen, 2008; Lascols et al.,
2003; Oleastro et al., 2003).
3.3. CLR resistance detection by E-Test® and Lightmix® RT-PCR using H.
pylori isolated from gastric biopsies
We determined the MIC of CLR by E-Test® for 6 H. pylori strains iso-
lated from gastric biopsies (Table 3). 1/6 strains were classiﬁed as CLR
susceptible (MIC ≤0.25 mg/L) and 5/6 strains were classiﬁed as CLR re-
sistant (0.5 bMIC). 2/6 showed a Tmat 56 °C (A2143G) and 2/6 showed
a Tm at 59 °C (A2142G). Two H. pylori strains showed a wild-type geno-
type at a Tm of 63 °C, though one was determined as CLR susceptible
(0.032 mg/L) and one as CLR resistant (1 mg/L) by E-Test®. 23S rDNA
sequencing conﬁrmed the wild-type sequence for the H. pylori
isolate (Table 3).
Fig. 1. Relationship between phenotypical CLR susceptibility testing by E-Test®
(≤0.25 mg/L relates to CLR susceptible; N0.5 mg/L relates to CLR resistant) and the
detected H. pylori genotypes in melting curve analysis using 60 H. pylori strains.
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3.4. Detection of H. pylori in stool specimens
Stool samples were spiked with 3 different H. pylori isolates (wild-
type, A2142G andA2143Ggenotype). Stool sampleswith initial concen-
trations of 109–104 CFUs/ml before DNA extraction showed a clear
ampliﬁcation signal in the H. pylori RT-PCR (Fig. 3a) and melting curve
analysis identiﬁed the correct H. pylori genotype (Fig. 3b).
Campylobacter jejuni and Campylobacter fetus showed a late ampliﬁ-
cation signal in the H. pylori RT-PCR (from the 35th cycle on) with an
ampliﬁcation delay of 10 cycles compared to the same amount of
H. pylori DNA, and gave a melting peak with a Tm at 63 °C in melting
curve analysis.
4. Discussion
Rapid detection and accurate identiﬁcation ofH. pylori and CLR resis-
tance genes is crucial for proper antibiotic therapy, and tomonitor resis-
tance epidemiology. Commercially available tests have several
advantages over laboratory-developed assays, i.e., production is highly
standardized, quality is controlled by the manufacturer, reagents are
ready to use, and the shelf-life of the test kits is guaranteed. Several
in-house RT-PCR assays for the genetic detection ofH. pylori and CLR re-
sistancewere previously published (e.g., 19). The LightMix®H. pylori kit
is a new, commercially available RT-PCR assay for the detection of
H. pylori and CLR resistance from cultures and biopsies. The limit of de-
tection of the Lightmix® RT-PCR was found at 103 CFUs/ml, which cor-
responds well with the assay information provided by TIBMolbiol.
Melting curve analysis always detected the correct H. pylori genotype
independent of the 23S rRNA gene copy number present in the assay.
Our results showed that different point mutations are associated with
different levels of CLR resistance as the A2142G and A2142C point
mutations were always related to high CLR resistance levels (MIC
≥256 mg/L).
In contrast, phenotypical susceptibility testing is very time consum-
ing (10 to 14 days) by conventional methods (e.g., E-Test®) and pre-
sents challenges due to H. pylori's slow growth and its fastidious
growth requirements. Moreover, we observed in our study that it is
not always possible to determine an explicit MIC of CLR with the E-
Test®, because of the small and transparent colonies that H. pylori
forms and the inter-assay variability depending on the analyst
performing the E-Test®. Furthermore, low bacterial loads after eradica-
tion treatment and overgrowth of contaminating microorganism can
reduce the sensitivity of cultural testing methods (Chisholm and
Owen, 2008).
We found high concordance (95%) for H. pylori and CLR resistance
detection in cultures and biopsies by E-Test® and Lightmix® RT-PCR.
Four bacterial isolates showed a CLR resistant phenotype determined
by E-Test® and a CLR susceptible genotype detected by Lightmix® RT-
PCR. 23S rDNA sequencing conﬁrmed the CLR susceptible genotype de-
tected in the Lightmix® RT-PCR and melting curve analysis. Discrepant
results between phenotypical and genotypical CLR susceptibility
screeningmay be explained by the fact that the Lightmix®H. pylori spe-
ciﬁc probe covers the 3most prevalent pointmutations in the 23S rRNA
gene (A2142G, A2143G and A2142C), but not all rarely occurring ones
(e.g. point mutation C2182T) (Chen et al., 2008). Except for 23S rRNA
mutations, expression of an active drug efﬂux mechanism, responsible
for rapidly transferring clarithromycin out of the bacterial cell, and
preventing the binding of the antibiotic to the ribosome, may play an
important role in acquired CLR resistance (Hirata et al., 2010; Webber
and Piddock, 2003).
Detection of H. pylori in stool specimens was very accurate and the
correct genotype was characterized in melting curve analysis for all
H. pylori isolates. The limit of detection was found at 104 DNA copies
per ml that corresponds well with previous studies (Schabereiter-
Gurtner et al., 2004). However, C. jejuni and C. fetus produced unspeciﬁc
positive results if present in high concentrations. We therefore decided
to complement the H. pylori RT-PCR with a CE-IVD labeled genus
speciﬁc probe for Campylobacter (TIBMolbiol), and always used duplex
RT-PCRs for H. pylori detection in clinical specimens. This allowed us
to detect Campylobacter spp. when present in clinical samples (biopsy
and feces), and avoid false positive results for H. pylori detection.
Fig. 2. Melting curve analysis of 60 H. pylori strains showing phenotypical CLR
susceptibility with MIC ≤0.25 mg/L (a); CLR resistance with 0.5 b MIC b256 mg/L (b),
and CLR resistance with MIC ≥256 mg/L (c).
Table 2
Results from CLR resistance detection with the E-Test® and the Lightmix® H. pylori RT-
PCR in H. pylori strains (N = 60).
E-Test®
Susceptible to CLR Resistant to CLR
RT-PCR
Susceptible to CLR 20 3
Resistant to CLR 0 37
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In conclusion, our data showed that there is a strong association be-
tween speciﬁc mutations in the 23S rDNA and CLR resistance. The RT-
PCR proved to be an exceptional tool for a fast and reliable detection
of H. pylori. Furthermore, it allows for CLR resistance screening within
a few hours prior to the prescription of an antibiotic therapy and should
drastically reduce the cases of treatment failure as CLR is just
administered if no resistance is detected. These improved detection
rates and antibiotic susceptibility information is especially important
when H. pylori culture is unsuccessful.
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